This chart does one thing: for each of the 52 compounds this site's calculators cover, it records the dose range that the strongest available source states, says what kind of source that is, and dates the reading. It replaces a free reference chart that used to sit on a store's guide hub, and it was rebuilt from the sources rather than copied.
The grading matters more than the numbers. A label figure was set by a regulator for a named population and indication. A trial protocol figure was chosen by investigators for a study and carries that study's route, schedule and population. A compounding reference is a pharmacy's stated concentration and cited range for a product that has no approval. Vendor pages are the figures that circulate on product and protocol pages, dated here, with no study behind them unless the row says otherwise. The compound's own page, linked in the first column, converts each figure into U-100 syringe units at that compound's vial sizes; the dosage hub lists them all, and Medibact's peptide guide library carries the evidence behind each compound.
The chart
Compounds whose dosage page is still being written link their calculator page instead; each row is re-pointed the day its page ships.
| Compound | Reported range, as the best source states it | Source type | Date read |
|---|---|---|---|
| 5-Amino-1MQ | Oral 50 to 150 mg once daily; injectable 2.5 to 5 mg once daily. Not a peptide; no human study. | Vendor pages | 2026-09-18 |
| AOD-9604 | Oral 0.25 to 30 mg daily for 12 to 24 weeks and single intravenous infusions of 25 to 400 mcg/kg across six sponsor trials, 893 subjects (Stier 2013). No subcutaneous trial; vendor pages 300 to 500 mcg/day SC. | Trial protocol | 2026-09-18 |
| ARA-290 | 4 mg SC daily for 28 days (Brines 2015); 1, 4 or 8 mg/day (Culver 2017); 2 mg IV three times weekly for 4 weeks (Heij 2012). | Trial protocol | 2026-09-18 |
| BPC-157 | No human dose in the indexed literature; a 2026 phase 2 (NCT07437547) and a phase 1 of daily SC injection for 90 days (NCT07803250) post no amount. Vendor pages 250 to 500 mcg SC once or twice daily. | Vendor pages | 2026-09-18 |
| Cagrilintide | 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly SC (Lau 2021, phase 2, 26 weeks); 2.4 mg weekly with semaglutide 2.4 mg (Garvey 2025, phase 3, 68 weeks). | Trial protocol | 2026-09-18 |
| Cartalax | No indexed human trial (PubMed does not hold the term). Vendor pages 2 to 5 mg SC daily over 12 weeks, or 10 mg daily for 20 days. | Vendor pages | 2026-09-18 |
| CJC-1295 | DAC form: single SC doses of 30 to 90 mcg/kg, weekly or biweekly at 30 to 60 mcg/kg (Teichman 2006; Ionescu 2006). Vendor pages: DAC 1 to 2 mg/week; no-DAC 100 to 300 mcg one to three times daily. | Trial protocol | 2026-09-18 |
| CJC-1295 + Ipamorelin | No trial of the combination. Vendor and clinic pages 100 to 300 mcg of each per injection, one to three times daily, from a 10 mg blend vial at 2 mL. | Vendor pages | 2026-09-18 |
| DSIP | 25 nmol/kg IV in the 1981 to 1987 insomnia trials; 25, 50 or 100 nmol/kg IV bolus (Pomfrett 2009, 24 patients). Vendor pages 100 to 300 mcg SC in the evening. | Trial protocol | 2026-09-18 |
| Epithalon | No human dose-finding study among 120 indexed records; 10 mcg/day IM in aged monkeys (Goncharova 2003). Vendor pages 5 mg/day for 20 days or 10 mg/day for 10 days. | Vendor pages | 2026-09-18 |
| Follistatin 344 | No human injectable data (the human record is gene therapy). Vendor pages 100 to 200 mcg SC daily, up to 300 mcg, in 2 to 4 week blocks. | Vendor pages | 2026-09-18 |
| GHK-Cu | Topical 0.1% gel, about 0.5 g once daily for 14 days (NCT07437586, phase 2, 2026); no human injection study. Vendor pages 1 to 2 mg SC daily. | Trial protocol (topical) | 2026-09-18 |
| GHRP-2 | Oral 900 mcg/kg twice daily for 12 months in GH-deficient children (Mericq 2003); a single 100 mcg IV dose as a diagnostic test in Japan (vendor page; diagnostic status per a 2004 review). Vendor pages 100 to 300 mcg SC two to three times daily. | Trial protocol | 2026-09-18 |
| GHRP-6 | 1 mcg/kg IV single dose (Peñalva 1993, 37 subjects); 90 mcg IV bolus (Micic 1995); oral 300 mcg/kg twice daily for 4 days (Ghigo 1994). Vendor pages 100 to 300 mcg SC three times daily. | Trial protocol | 2026-09-18 |
| Glutathione | No FDA label. Compounding: 200 mg/mL; 600 to 1,400 mg IV per session two to three times weekly. Trials: 1,400 mg IV three times weekly (Hauser 2009); 2,500 mg IV before angioplasty and at 24, 48 and 72 h (Tanzilli 2019, 2021); 600 mg IV twice daily for 5 days (NCT06296212). | Compounding reference and trial protocol | 2026-09-18 |
| Gonadorelin | 100 mcg IV bolus as a stimulation test (Casper 2000); 100 mcg IV per pulse by pump (Fenichel 1988). No current US label (openFDA: none). Vendor pages 50 to 250 mcg SC two to three times weekly. | Trial protocol | 2026-09-18 |
| Hexarelin | Single doses in healthy volunteers: 0.5, 1 or 2 mcg/kg IV (Imbimbo 1994); 1.5 and 3 mcg/kg SC, 20 mcg/kg intranasal, 20 and 40 mg oral (Ghigo 1994). Vendor pages 100 mcg SC one to three times daily. | Trial protocol | 2026-09-18 |
| HGH Fragment 176-191 | No human trial of the fragment itself (the human trials are AOD-9604's). Vendor pages 200 to 500 mcg SC once or twice daily in 4-week cycles (page dated 2024-02-09). | Vendor pages | 2026-09-18 |
| IGF-1 LR3 | No human dosing study among 25 human-tagged records (one is an analysis of a black-market vial). Vendor pages 20 to 100 mcg SC daily in 4 to 6 week cycles. | Vendor pages | 2026-09-18 |
| Ipamorelin | IV infusions of 4.2 to 140 nmol/kg (about 3 to 100 mcg/kg) over 15 minutes (Gobburu 1999); 0.03 mg/kg IV twice daily for 7 days (Beck 2014, 114 patients); 0.06 mg/kg arms registered (NCT01280344). Vendor pages 100 to 300 mcg SC one to three times daily. | Trial protocol | 2026-09-18 |
| Kisspeptin-10 | IV bolus 0.01 to 3 mcg/kg and infusion 1.5 to 4 mcg/kg/h (George 2011); 0.3 to 1 nmol/kg IV and 32 nmol/kg SC (Jayasena 2011); healthy men and women. | Trial protocol | 2026-09-18 |
| KPV | No human study, label or registration. Vendor pages: oral 250 to 500 mcg once or twice daily; SC 200 to 500 mcg daily; topical 0.1 to 1%. | Vendor pages | 2026-09-18 |
| LL-37 | Topical 0.5, 1.6 or 3.2 mg/mL twice weekly on venous leg ulcers for 4 weeks (Grönberg 2014, 34 patients; Mahlapuu 2021, 148). No injection study. Vendor pages 100 to 250 mcg SC daily. | Trial protocol (topical) | 2026-09-18 |
| Mazdutide | 4 mg and 6 mg once weekly SC (Zhu 2026; Guo 2026, phase 3, 320 and 731 adults); titrations to 9 mg and 10 mg in phase 1b (Ji 2022). Approved in China in 2025; label not opened. | Trial protocol | 2026-09-18 |
| Melanotan 1 | Afamelanotide (Scenesse) label: one 16 mg subcutaneous implant every 2 months (openFDA label, effective 2026-05-11). | Label | 2026-09-18 |
| Melanotan II | SC 0.01 mg/kg rising to 0.025 to 0.03 mg/kg daily on weekdays for 2 weeks (Dorr 1996, 3 men); 0.025 mg/kg (Wessells 2000, 20 men). Vendor pages 100 to 1,000 mcg daily while loading. | Trial protocol | 2026-09-18 |
| MGF | No human data. Vendor pages 100 to 300 mcg SC once daily, or 100 to 200 mcg IM after exercise. | Vendor pages | 2026-09-18 |
| Mod GRF 1-29 | No human study of the no-DAC form. Vendor pages 100 to 300 mcg SC one to three times daily (the "CJC-1295 no DAC" figures). | Vendor pages | 2026-09-18 |
| MOTS-c | No published human dose; a 2026 phase 2 SC trial (NCT07505745) posts none. Vendor pages 5 to 10 mg SC two to three times weekly for 4 to 8 weeks. | Vendor pages | 2026-09-18 |
| NA-Selank Amidate | No human study of the amidate. Vendor pages 200 to 600 mcg per dose, intranasal or SC, one to three times daily; 600 to 900 mcg/day in 14-day cycles. | Vendor pages | 2026-09-18 |
| NA-Semax Amidate | No human study of the amidate. Vendor pages 200 to 600 mcg/day SC or intranasal, or 400 to 900 mcg/day intranasal in two to three doses. | Vendor pages | 2026-09-18 |
| NAD+ | No label. 100 mg in 2 mL IM, SC or IV push (NCT06919328); 10 mg IV daily for 7 days (Yu 2026, 180 patients); 3 micromoles/min IV for 6 h (Grant 2019). Clinic pages SC 10 to 100 mg, IV 100 to 1,000 mg. | Trial protocol | 2026-09-18 |
| Oxytocin | Pitocin label: 0.5 to 1 mU/min IV to start, raised by 1 to 2 mU/min every 30 to 60 minutes, rarely above 9 to 10 mU/min; 10 units after delivery of the placenta (openFDA label, effective 2026-05-06). Research intranasal 24 IU (Guastella 2008). | Label | 2026-09-18 |
| PE-22-28 | No human data. Vendor pages 50 to 200 mcg SC daily; rodent work at 100 to 500 mcg/kg. | Vendor pages | 2026-09-18 |
| PEG-MGF | No human data. Vendor pages 200 to 500 mcg SC daily, or 100 to 250 mcg twice weekly. | Vendor pages | 2026-09-18 |
| Pinealon | 100 mcg twice daily for 2 weeks in a Russian occupational study (Nazimko 2012; route not in the abstract). Vendor pages 1 to 2 mg SC daily for 10 to 20 days; oral 20 mg. | Trial protocol (Russian) | 2026-09-18 |
| PT-141 | Vyleesi label: 1.75 mg SC as needed, at least 45 minutes before activity; not more than one dose in 24 h; more than 8 a month not recommended (DailyMed, label revised March 2024). | Label | 2026-09-18 |
| Retatrutide | 1, 4, 8 or 12 mg once weekly SC for 48 weeks, with 2 mg or 4 mg starting doses (Jastreboff 2023, phase 2, 338 adults). | Trial protocol | 2026-09-18 |
| Selank | Russian registration: 0.15% nasal drops (1.5 mg/mL), regimen "individual" on the entry (vidal.ru, registered 2025-07-15). Vendor pages citing the trials: 250 to 750 mcg intranasal two to three times daily for 14 days; SC 300 to 500 mcg daily. | Label (Russia) | 2026-09-18 |
| Semaglutide | Wegovy label: 0.25 mg once weekly for 4 weeks, then 0.5, 1 and 1.7 mg in 4-week steps; maintenance 2.4 mg (or 1.7 mg) once weekly (openFDA label, effective 2026-09-18). | Label | 2026-09-18 |
| Semax | Russian registrations: 0.1% drops (50 mcg per drop), 2 to 3 drops per nostril four times daily for 10 to 14 days; 1% drops (500 mcg per drop) for acute stroke, 6,000 to 20,000 mcg/day for 10 days (vidal.ru); 6,000 mcg/day in a 110-patient stroke study (Gusev 2018). | Label (Russia) | 2026-09-18 |
| Sermorelin | Geref label (discontinued 2008): 30 mcg/kg SC once daily at bedtime in children with GH deficiency; no current US label (openFDA: none). Vendor pages 200 to 300 mcg SC nightly. | Label (historical) | 2026-09-18 |
| SLU-PP-332 | No human trial; mice 25 to 50 mg/kg intraperitoneally (Billon 2023). Vendor pages oral 25 to 100 mg daily; SC 250 mcg to 1.5 mg daily. | Vendor pages | 2026-09-18 |
| SS-31 | Forzinity (elamipretide) label: 40 mg SC once daily in Barth syndrome at 30 kg or more; 20 mg if eGFR is under 30; 80 mg/mL vials (openFDA label, effective 2025-12-10). | Label | 2026-09-18 |
| Survodutide | 3.6 mg and 6.0 mg once weekly SC in the phase 3 programme (Yokote 2026); 0.3 to 2.7 mg once weekly and 1.2 to 1.8 mg twice weekly in phase 2 (Blüher 2024, 411 patients). | Trial protocol | 2026-09-18 |
| TB-500 | No human trial of the fragment; a 2026 phase 1/2 (NCT07487363) posts no dose. Full-length thymosin beta-4 IV 0.05 to 25 mcg/kg (NCT04555824). Vendor pages 2 to 2.5 mg SC twice weekly, then weekly. | Vendor pages | 2026-09-18 |
| Tesamorelin | Egrifta WR label: 1.28 mg SC once daily; an 11.6 mg vial with 1.3 mL of diluent gives 8 mg/mL and 0.16 mL per dose (openFDA label, effective 2026-09-18). | Label | 2026-09-18 |
| Thymalin | Russian registration: 5 to 20 mg IM daily for 3 to 10 days, 30 to 100 mg per course, repeated after 1 to 6 months; 10 mg vials (vidal.ru, registered 2024-06-21). | Label (Russia) | 2026-09-18 |
| Thymosin Alpha-1 | Thymalfasin 1.6 mg SC twice weekly for 6 to 12 months in hepatitis B and post-resection liver cancer trials (Chien 2004; Qiu 2015); 1.6 mg five times weekly for 24 weeks (Gish 2009). Approved outside the US; label not opened. | Trial protocol | 2026-09-18 |
| Thymulin | The 1987 open rheumatoid-arthritis trial abstract (Faure 1987) states no dose; no other human dose in the indexed record. Vendor pages 250 to 750 mcg SC daily in 10 to 20 day blocks. | Vendor pages | 2026-09-18 |
| Tirzepatide | Zepbound label: 2.5 mg SC once weekly for 4 weeks, then 2.5 mg steps after at least 4 weeks on each; maintenance 5, 10 or 15 mg; maximum 15 mg weekly (openFDA label, effective 2026-09-18). | Label | 2026-09-18 |
| VIP | Aviptadil IV at 50, 100 and 150 pmol/kg/h escalating over 12 hours in critical COVID-19 (NCT04311697, 203 randomised). Vendor pages intranasal 50 mcg per spray, 4 to 8 sprays daily; SC 50 to 200 mcg. | Trial protocol | 2026-09-18 |
How to read the chart
The second column is a quotation in compressed form, not a summary of consensus. Where a row holds two figures with a semicolon between them, they come from different sources and are not reconciled; where it holds a nil result ("no human study", "posts no dose"), that absence was checked on the date shown and is itself the finding. Per-kilogram figures stay per kilogram: converting them to a fixed milligram amount needs a body weight, and the compound pages do that arithmetic at 70 kg with the assumption stated. A route in a row is the source's route; a vendor page's subcutaneous figure sitting beside a trial's intravenous or oral one is the pattern the chart exists to show, and it appears in more than a third of the rows.
Three compounds are dosed in units that are not milligrams. Oxytocin's label is in milliunits per minute of an infusion. DSIP and kisspeptin-10 are reported in nanomoles per kilogram, because the original papers used molar doses. NAD+'s one pharmacokinetic study is a rate in micromoles per minute. The compound pages give the molar-mass conversion where it helps.
What the chart does not do
It does not state a dose for anyone, does not rank the sources beyond naming their type, and does not say that a figure on a vendor page is wrong or right; it says that no study tested it, when that is the case. It does not carry syringe units, because units depend on the vial and the water, which the compound pages and the reconstitution calculator handle at each vial size. It does not cover storage, shelf life or the mixing procedure, which are the store's topics: how to reconstitute peptides and how to store peptides on medibact.com. And it does not stay still: the date on each row is the date it was last checked, and a row is only as current as that date.
Sources and dates
Opened 2026-09-18: DailyMed's SPL search API and FDA's openFDA drug-label API for the labelled compounds (Vyleesi, Wegovy, Zepbound, Egrifta WR, Pitocin, Forzinity, Scenesse; sermorelin and gonadorelin returned no current label); the vidal.ru drug reference for the Russian registrations of Semax 0.1% and 1%, Selank 0.15% and Thymalin; PubMed through the NCBI E-utilities for the trial abstracts named in the rows and for the census counts; the ClinicalTrials.gov v2 API for the registrations named in the rows; the open-access full text of Stier, Vos and Kenley 2013 for AOD-9604; PubChem for molecular weights; and dated vendor, clinic and compounding pages for the rows graded that way. Corrections go to the contact page.